// App-Quantinova.ai

SAT0396 : SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2)

Researchers

Presenter

  • H. Marzo-Ortega

Principal Investigators

  • C.W. Legerton

  • J. Sieper

  • A. Kivitz

  • R. Blanco

  • M. Cohen

  • J. Zuazo

  • A. Readie

  • B. Porter

  • H. Richards

Medical Centers

  • Altoona Center for Clinical Research, Duncansville, PA

  • University Clinic Benjamin Franklin, Berlin, Germany

  • Division of Cancer Epidemiology, McGill University, Montreal, Canada

  • NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leed & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • Low Country Rheumatology, Articularis Healthcare, Charleston, United States

Locations

  • Canada

  • Germany

  • Spain

  • United Kingdom

  • United States

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

  • Spondyloarthritis

Biomarkers

  • High sensitivity C-reactive protein

Drug/Treatment

  • secukinumab

  • Sandolase

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved